Kymera Stock 130%: $135 Million Buy Boosts Immunology Bet
A major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
Knowing when to use cash back versus rewards points can enhance your savings. Our guide provides insights for better decision-making.
26,047 articlesA major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
AI advances hinge on memory tech. As the world’s top HBM maker becomes accessible to U.S. investors, learn how this s...
When geopolitics roils markets, the duration of the shock matters most. This week, investors should focus on how long...
Imagine a Corcept director with 1.5 million shares weathering a 50% stock crash and a strong rebound. This article br...
Can bloom energy stock going to $200 actually happen? This guide breaks down the catalysts, risks, and practical stra...
A colossal AI infrastructure agreement links Meta Platforms with Nebius in a five-year plan worth $27 billion. This a...
Li Lu’s Himalaya Capital is famous for a bold, value-driven stance and a striking concentration in just a few bets. T...
March has delivered a mixed bag for investors as oil swings, AI news, and private credit worries collide. This guide ...
When a software company posts strong results and outlines a confident path forward, investors often push the stock hi...
Two space stocks down sharply in a single month, but the bigger question is which one offers the better chance to reb...
What if a growth stock turned $10,000 into $423,000? This article breaks down that extraordinary trajectory, what it ...
When a Opendoor director sells a sizable stake, investors wonder if it hints at trouble or simply liquidity needs. Th...